Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

100 patients with Breakthrough pain will be allocated to receive either oral prioxicam (OP) (n=50) or sublingual fentanyl (SLF) (n=50) . Patients will be divided randomly into two equal groups: oral prioxicam (OP) Group and sublingual fentanyl citrate (SLF) Group, comprising of 50 patients each.

Pain intensity level on a 0-10 visual analog scale (VAS), patients will be instructed about the use of a 10-cm visual analog scale (VAS) (0 = no pain to 10 = worst possible pain). frequency of Breakthrough pain throughout the day, onset of relief (0-5, 6-10, 11-15, or over 16 min), time required for dose titration, patient satisfaction and adverse effects were assessed at 3, 7, 15, and 30 days after starting the treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Fentanyl; Piroxicam

Criteria

Inclusion Criteria:

Eligible participants were all:

• adults aged 18 or over

• suffering from Background pain cancer pain

• whose cancer pain was treated with strong opioids and

• who had breakthrough pain which met the criteria described by Portenoy.

Exclusion Criteria:

Exclusion criteria were:

• less than18 years old,

• non-controlled basal pain,

• hospitalized patients, or cognitive disturbances,

• patients with contraindication to NSAIDS such as:

• gastric ulcer,

• impaired renal function,

• cerebrovascular accident,

• coronary artery bypass graft,

• uncontrolled hypertension,

• patients with coagulation anomalies such as hepatic disease or

• patients a previous history of allergy to NSAID.